Compare Stocks → Trump Reveals Conspiracy Behind Fed-Controlled Digital Currency. (From Monetary Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ELDNNASDAQ:JAGXNASDAQ:KZRNYSEAMERICAN:MAIA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.02+7.9%$2.00$1.07▼$3.29$69.48M0.86326,095 shs611,121 shsJAGXJaguar Health$0.26-10.4%$0.16$0.05▼$0.75$71.40M0.8958.90 million shs58.06 million shsKZRKezar Life Sciences$0.77$0.84$0.67▼$3.13$55.74M0.47666,344 shs266,034 shsMAIAMAIA Biotechnology$3.31+6.1%$0.00$0.82▼$3.59$68.13M0.04315,952 shs423,186 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals+7.86%+30.74%+92.36%+65.03%+34.22%JAGXJaguar Health-9.84%-11.50%+56.76%+230.99%-61.98%KZRKezar Life Sciences-0.30%-0.91%-6.23%-8.85%-72.85%MAIAMAIA Biotechnology0.00%0.00%0.00%0.00%+116,999,900.00%The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.8194 of 5 stars3.53.00.00.03.81.70.6JAGXJaguar Health0.177 of 5 stars0.03.00.00.02.40.00.6KZRKezar Life Sciences3.6858 of 5 stars3.21.00.04.62.71.70.6MAIAMAIA Biotechnology0.1623 of 5 stars0.02.00.00.01.13.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals3.00Buy$11.67286.31% UpsideJAGXJaguar HealthN/AN/AN/AN/AKZRKezar Life Sciences2.33Hold$11.001,336.59% UpsideMAIAMAIA BiotechnologyN/AN/AN/AN/ACurrent Analyst RatingsLatest MAIA, JAGX, ELDN, and KZR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/7/2024ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $16.003/22/2024ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.003/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 5/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$3.02 per shareN/AJAGXJaguar Health$9.76M7.32N/AN/A$0.04 per share6.46KZRKezar Life Sciences$7M7.96N/AN/A$2.32 per share0.33MAIAMAIA BiotechnologyN/AN/AN/AN/A($0.26) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$40.33M-$1.38N/AN/AN/AN/A-45.60%-42.76%8/8/2024 (Estimated)JAGXJaguar Health-$41.30MN/A0.00N/AN/A-377.95%-642.15%-75.53%8/12/2024 (Estimated)KZRKezar Life Sciences-$101.87M-$1.40N/AN/AN/AN/A-47.28%-40.79%8/8/2024 (Estimated)MAIAMAIA Biotechnology-$19.77M-$1.58N/A∞N/AN/A-2,189.07%-282.82%N/ALatest MAIA, JAGX, ELDN, and KZR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024JAGXJaguar HealthN/A-$0.06-$0.06-$0.06N/A$2.35 million 3/28/2024Q4 2023ELDNEledon Pharmaceuticals-$0.38-$0.29+$0.09-$0.29N/AN/A3/21/2024Q4 2023MAIAMAIA Biotechnology-$0.35-$0.41-$0.06-$0.41N/AN/A3/14/2024Q4 2023KZRKezar Life Sciences-$0.39-$0.35+$0.04-$0.26N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A11.3014.41JAGXJaguar Health1.841.891.34KZRKezar Life Sciences0.0511.4811.49MAIAMAIA BiotechnologyN/A1.771.53OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%JAGXJaguar Health12.04%KZRKezar Life Sciences67.90%MAIAMAIA Biotechnology5.65%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals19.40%JAGXJaguar Health0.16%KZRKezar Life Sciences7.90%MAIAMAIA Biotechnology36.98%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals2024.81 million20.00 millionOptionableJAGXJaguar Health49276.22 million275.77 millionNo DataKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableMAIAMAIA Biotechnology1321.84 million13.76 millionNot OptionableMAIA, JAGX, ELDN, and KZR HeadlinesRecent News About These CompaniesMay 17 at 8:37 AM | businesswire.comMAIA Biotechnology to Present at the BIO International Convention 2024May 16 at 8:37 AM | businesswire.comMAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual MeetingMay 15 at 11:20 AM | investorplace.comMAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024May 10, 2024 | bovnews.comWhy MAIA Biotechnology Inc (AMEX:MAIA) Stock down -8.25% in Last Week?May 7, 2024 | vegconomist.comMaia Farms Secures $2.3M to Advance Climate Positive Food with Highly Nutritious MycoproteinApril 30, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementApril 29, 2024 | marketwatch.comMAIA Biotechnology Shares Hit 52-Week High After Director Stock PurchaseApril 29, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private PlacementApril 28, 2024 | finance.yahoo.comMAIA Biotechnology, Inc. (MAIA)April 27, 2024 | insidertrades.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ngar Yee Louie Acquires 19,665 SharesApril 26, 2024 | marketbeat.comMAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires $39,919.95 in StockApril 23, 2024 | businesswire.comMAIA Biotechnology Announces $1.00 Million Private PlacementApril 18, 2024 | dailycamera.comBoulder-area events for Wednesday, April 17: Yoga at Eben G Fine ParkApril 18, 2024 | dailycamera.comBoulder-area events for Thursday, April 18: ‘Creative Path of Motherhood’ exhibitApril 12, 2024 | alzheimersnewstoday.comNK cell therapy seen to slow cognitive decline in Phase 1 trialApril 5, 2024 | businesswire.comMAIA Biotechnology to Present at Two Investor Conferences in April 2024April 4, 2024 | msn.comeFFECTOR shelves tomivosertib in NSCLC following Phase II failureApril 3, 2024 | labiotech.euChicago biotech: Seven players advancing the industryMarch 28, 2024 | investing.comMAIA Biotechnology directors buy shares amid development pushMarch 28, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro GuerreroMarch 26, 2024 | businesswire.comMAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private PlacementNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEledon PharmaceuticalsNASDAQ:ELDNEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.MAIA BiotechnologyNYSEAMERICAN:MAIAMAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.